Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial

Zhang, J.; Li, M.; Zhang, K.; Zheng, A.; Li, G.; Chen, S.; Li, X.; Sheng, Y.; Sun, Xinyue; Liu, L.; Liu, X.; Li, J.; Wang, J.; Ge, H.; Ye, S.; Pang, Qiuyang; Zhang, X.; Dai, S.; Li, B.

doi:10.1016/j.ijrobp.2022.07.357

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhang et al. [ 48 ] similarly found no statistically significant difference in the OS and PFS of the patients in the EN and IFI groups. Meta-analyses have consistently concluded that IFI does not compromise local control or survival rates, while mitigating the adverse effects of radiotherapy compared to ENI [ 49 , 50 ].…”

Section: Discussionmentioning

confidence: 99%

Knowledge domains and emerging trends in radiotherapy in oesophageal cancer from 2004 to 2023: a bibliometric analysis and visualization study

Feng,

Lv,

Zeng

et al. 2024

Journal of Radiation Research

View full text Add to dashboard Cite

Esophageal cancer (EC) is a malignant tumour with high morbidity and mortality rates. Recent studies have shown that much progress has been made in the research of radiotherapy in EC. This study aims to provide a comprehensive overview of the knowledge structure and research hotspots of radiotherapy in EC through bibliometrics. Publications related to radiotherapy in EC from 2014 to 2023 were searched on the web of science core collection database. VOSviewers, CiteSpace and R package ‘bibliometrix’ were used to conduct this bibliometric analysis. In total, 4258 articles from 76 countries led by China and the USA were included. The Chinese Academy of Medical Sciences—Peking Union Medical College has the highest number of publications. International Journal of Radiation Oncology Biology Physics is the most popular journal and also the most co-cited journal in this field. These publications come from 21 972 authors among which Liao Zhongxing had published the most papers and Cooper JS was co-cited most often. Neoadjuvant chemoradiotherapy and strategies based on it are the main topics in this research field. ‘IMRT’ and ‘immunotherapy’ are the primary keywords of emerging research hotspots. This is a bibliometric study that comprehensively summarizes the research trends and developments of radiotherapy in EC. This information identifies recent research frontiers and hot directions, which will provide a reference for scholars studying radiotherapy in EC.

show abstract

Section: Discussionmentioning

confidence: 99%

Knowledge domains and emerging trends in radiotherapy in oesophageal cancer from 2004 to 2023: a bibliometric analysis and visualization study

Feng,

Lv,

Zeng

et al. 2024

Journal of Radiation Research

View full text Add to dashboard Cite

show abstract

“…Their results were inconsistent with our conclusion, which may be attributed to that most of the included studies in these me- Three ongoing prospective trials reported the preliminary results, which could not be enrolled in this meta-analysis. At the 2022 American Society for Therapeutic Radiology and Oncology (ASTRO), a multicenter phase III randomized clinical trial (NROG-001) [27] reported that the HD arm (59.4 Gy) did not present significantly prolonged OS (HR = 0.93, P = 0.54) but exhibited improved PFS (29.1 months to 20.0 months, HR = 0.77, P = 0.023) when compared with the SD arm (50.4 Gy) for local advanced thoracic ESCC. The ongoing Chinese ESO-Shanghai 12 study [28] and British SCOPE2 study [29] are making an earnest endeavor to compare the effects of standard-dose and high-dose radiation treatments.…”

Section: Discussionmentioning

confidence: 99%

Is Escalated Radiation Dose in Definitive Chemoradiotherapy Better for Inoperable Esophageal Carcinoma? A Meta-Analysis and Systematic Review

Gan¹,

Gou²,

Zhu³

et al. 2023

ABB

View full text Add to dashboard Cite

Purpose: This study aimed to compare the survival benefits between different total radiation doses in definitive chemoradiotherapy (dCRT) for inoperable esophageal carcinoma (EC) based on modern radiotherapy techniques. Methods: A systematic review was performed by searching the databases of PubMed, EMBASE, Cochrane Central Register of Controlled Trials and Web of Science. All studies published prior to November 30, 2022, comparing radiation dose and disease-related outcomes in EC patients. The hazard ratio (HR) and odds ratio (OR) were used to describe the risk of outcomes and toxicities. Results: Seven prospective trials involving 1124EC patients were enrolled for analyses. The results revealed that the effect on overall survival (HR = 0.99, 95% CI = 0.85 -1.16, P = 0.94), local progression-free survival (HR = 0.83, 95% CI = 0.58 -1.17, P = 0.29), local regional progression-free survival (HR = 0.94, 95% CI = 0.76 -1.17, P = 0.61), progression-free survival (HR = 0.90, 95% CI = 0.71 -1.13, P = 0.35) was similar in the high-dose and standard-dose groups. Additionally, a high radiation dose exhibited a potential disadvantage in respiratory toxicities when compared with a standard dose (4.8% vs 2.2%, OR 2.11, P = 0.06). Conclusions: The efficacy of the HD group (≥60 Gy) and the SD group (approximately 50 Gy) for inoperable local advanced EC was similar. However, the HD group exhibited a high radiation dose exhibited a potential disadvantage in respiratory toxicities when compared with a standard dose. Simultaneously, the final results of several ongoing prospective trials regarding the optimal radiation dose in dCRT are awaited.

show abstract

“…Most patients with esophageal cancer are in poor general condition and with advanced local disease, where treatment with the intention of surgery is impossible. A multicenter, randomized phase III trial (NROG-001) [31] showed that in the high-dose arm (59.4 Gy) there was no improvement in OS (HR = 0.93, p = 0.54), but an improvement in PFS was demonstrated (29.1 months-20.0 months, HR = 0.77, p = 0.023) compared with the lower dose arm (50.4 Gy). In the study by Herskovitz et al [32], the median OS was 8.9 months in the group with radiotherapy alone and 12.5 months in patients with radiochemotherapy.…”

Section: Brachytherapy Combined With Teleradiotherapy In Advanced Non...mentioning

confidence: 99%

The Role of Brachytherapy Alone and in Combined Treatment of Esophageal Cancer—A Review

Cisek,

Strąk,

Stachyra-Strawa

et al. 2024

Applied Sciences

View full text Add to dashboard Cite

Every year, over 600,000 new cases of esophageal cancer are registered worldwide. Treatment depends on the stage of the disease. In the early stages, surgical treatment is the basis (T1–T2 lesion < 3 cm, N0M0), while in more advanced stages, surgical treatment is preceded by radiochemotherapy or only radiochemotherapy is used. In the case of generalized disease, the main treatments used are systemic treatments of chemotherapy, immunotherapy and palliative teleradiotherapy or brachytherapy. Brachytherapy can be used at virtually any stage of disease, both as a radical treatment and as a palliative treatment. This paper presents the possibilities of using brachytherapy at various stages of esophageal cancer treatment. Particular attention was paid to the role of combining brachytherapy and immunotherapy and the possibility of an abscopal effect.

show abstract

Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial

Cited by 5 publications

References 0 publications

Knowledge domains and emerging trends in radiotherapy in oesophageal cancer from 2004 to 2023: a bibliometric analysis and visualization study

Knowledge domains and emerging trends in radiotherapy in oesophageal cancer from 2004 to 2023: a bibliometric analysis and visualization study

Is Escalated Radiation Dose in Definitive Chemoradiotherapy Better for Inoperable Esophageal Carcinoma? A Meta-Analysis and Systematic Review

The Role of Brachytherapy Alone and in Combined Treatment of Esophageal Cancer—A Review

Contact Info

Product

Resources

About